


This article was downloaded by: [Michigan State University]

On: 23 February 2015, At: 00:22

Publisher: Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Carbohydrate Chemistry

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/lcar20>

Chemical-Enzymatic Synthesis of A Branched Hexasaccharide Fragment of Type Ia Group B Streptococcus Capsular Polysaccharide

Wei Zou^a & Harold J. Jennings^a

^a Institute for Biological Sciences, National Research Council of Canada, Ottawa, Canada, K1A 0R6

Published online: 19 Aug 2006.

To cite this article: Wei Zou & Harold J. Jennings (1996) Chemical-Enzymatic Synthesis of A Branched Hexasaccharide Fragment of Type Ia Group B Streptococcus Capsular Polysaccharide, Journal of Carbohydrate Chemistry, 15:8, 925-937, DOI: [10.1080/07328309608005699](https://doi.org/10.1080/07328309608005699)

To link to this article: <http://dx.doi.org/10.1080/07328309608005699>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>

**CHEMICAL-ENZYMATIC SYNTHESIS OF
A BRANCHED HEXASACCHARIDE FRAGMENT OF TYPE Ia GROUP B
STREPTOCOCCUS CAPSULAR POLYSACCHARIDE**

Wei Zou and Harold J. Jennings*

Institute for Biological Sciences, National Research Council of Canada, Ottawa,
Canada K1A 0R6

Received February 12, 1996 - Final Form June 24, 1996

ABSTRACT

A branched hexasaccharide fragment of type Ia group B streptococcal polysaccharide, α -NeuAc(2 \rightarrow 3)- β -D-Gal(1 \rightarrow 4)- β -D-GlcNAc(1 \rightarrow 3)-[β -D-Glc(1 \rightarrow 4)]- β -D-Gal(1 \rightarrow 4)- β -D-Glc-OMe (**13**), has been synthesized by chemical-enzymatic procedures. Chemical synthesis of a pentasaccharide, β -D-Gal(1 \rightarrow 4)- β -D-GlcNAc(1 \rightarrow 3)-[β -D-Glc(1 \rightarrow 4)]- β -D-Gal(1 \rightarrow 4)- β -D-Glc-OMe (**12**), was achieved from glycosyl donor, 4-*O*-(2,3,4,6-tetra-*O*-acetyl- β -D-galactopyranosyl)-3,6-di-*O*-acetyl-2-deoxy-2-phthalimido- β -D-glucopyranosyl trichloroacetimidate (**9**), and acceptor, methyl *O*-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyl)-(1 \rightarrow 4)-*O*-(2,6-di-*O*-benzyl- β -D-galactopyranosyl)-(1 \rightarrow 4)-2,3,6-tri-*O*-benzyl- β -D-glucopyranoside (**6**), by block condensation in 41% yield. Following enzymatic sialylation of **12** at the 3-*O*-position of its terminal galactopyranosyl residue using recombinant α -(2 \rightarrow 3)-sialyltransferase and CMP-NeuAc afforded **13** in 59% yield.





Figure 1. Repeating-unit structures of GBS type Ia and Ib polysaccharides

INTRODUCTION

Group B *Streptococcus* (GBS) is the leading cause of bacterial infection among neonates.¹ Organisms of capsular types Ia and Ib together account for 40-50% of the cases of early-onset GBS disease.¹ The type Ia and Ib capsular polysaccharides have chemically similar structures.^{2,3} The sole difference between these polysaccharides is the bond between the galactose and *N*-acetylglucosamine residues in the side chain. These sugars are $\beta(1\rightarrow 4)$ -linked in type Ia and $\beta(1\rightarrow 3)$ -linked in type Ib (see Figure 1). Although the two polysaccharides are structural isomers, they are antigenically distinct; whereas antisera raised to type Ia organisms reacts strongly with type Ia polysaccharide, it reacts to a much lesser extent with type Ib polysaccharide.³ As a consequence of this, both polysaccharides will be required as components of any future comprehensive vaccine against meningitis caused by group B streptococci.⁴ Interestingly, in contrast to type Ib polysaccharide, type Ia produces a distinct population of antibodies entirely dependent on the presence of terminal sialic acid.⁵ This has been attributed to a sialic acid-controlled conformational epitope exhibited by type Ia polysaccharide but not by type Ib polysaccharide.⁵ Therefore, as part of our program to understand the role of sialic acid in the formation of conformational epitopes of capsular polysaccharides, a branched hexasaccharide fragment of type Ia polysaccharide was required to serve as a probe to define the epitope. Here, we describe the synthesis of this unit by a combined chemical-enzymatic protocol; the chemical synthesis of branched pentasaccharide **12** is followed by enzymatic sialylation with recombinant α -(2 \rightarrow 3)-sialyltransferase and CMP-NeuAc to afford hexasaccharide **13**.

RESULTS AND DISCUSSION

Methyl 4-*O*-(3-*O*-allyl-2-*O*-benzyl-4,6-di-*O*-benzylidene- β -D-galactopyranosyl)-2,3,6-tri-*O*-benzyl- β -D-glucopyranoside (**2**) was obtained in 78% yield from lactose derivative **1**⁶ by conventional benzylation with BnBr/NaH in DMF. Reductive ring-opening of benzylidene acetal by treatment **2** with sodium cyanoborohydride⁷ and HCl in THF afforded compound **3** in 69% yield. Condensation of **3** with 2,3,4,6-tetra-*O*-acetyl- α -D-glucopyranosyl trichloroacetimidate (**4**) in dichloromethane at -45 °C in the presence of trimethylsilyl triflate gave methyl *O*-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyl)-(1 \rightarrow 4)-*O*-(3-*O*-allyl-2,6-di-*O*-benzyl- β -D-galactopyranosyl)-(1 \rightarrow 4)-2,3,6-tri-*O*-benzyl- β -D-glucopyranoside (**5**) in 75% yield. Removal of the 3^b-*O*-allyl group in **5** was then achieved by treatment with PdCl₂ in methanol,⁸ to afford **6** in 71% yield.



Although compound **9** has been previously synthesized from lactosamine,^{6,9-11} we prepared this compound from 2-(trimethylsilyl)ethyl 4-*O*-(2,3,4,6-tetra-*O*-acetyl- β -D-galactopyranosyl)-3-*O*-acetyl-2-deoxy-2-phthalimido- β -D-glucopyranoside (**7**)¹² in three steps. Conversion of **7** into compound **8** by acetylation at the 6^b-*O*-position with acetic anhydride in pyridine (81% yield) followed by removal of the 2-(trimethylsilyl)ethyl group with boron trifluoride etherate,¹³ and finally treatment with trichloroacetonitrile in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU)¹⁴ to furnish compound **9** in 40% yield (two steps). The yield of **9** from **8** can be improved to 77% through the use of trifluoroacetic acid to remove 2-(trimethylsilyl)ethyl group¹³ and anhydrous K₂CO₃ as base in the formation of trichloroacetimidate.¹⁵ The ¹H NMR and physical data of this compound were in accordance with those reported in the literature.⁹⁻¹¹

Condensation of **6** with **9** in dichloromethane at -45 °C using trimethylsilyl triflate as promoter afforded methyl *O*-(2,3,4,6-tetra-*O*-acetyl- β -D-galactopyranosyl)-(1 \rightarrow 4)-*O*-(3,6-di-*O*-acetyl-2-deoxy-2-phthalimido- β -D-glucopyranosyl)-(1 \rightarrow 3)-*O*-[2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyl-(1 \rightarrow 4)-*O*]-[2,6-di-*O*-benzyl- β -D-galactopyranosyl)-(1 \rightarrow 4)-2,3,6-tri-*O*-benzyl- β -D-glucopyranoside (**10**) in 41% yield. The ¹³C NMR spectrum of **10** showed five anomeric carbon resonances at 99.99, 101.17, 101.31, 101.61, and 104.64 ppm, and its FABMS spectrum was also consistent with the proposed structure.

Compound **10** was treated with hydrazine hydrate in 95% ethanol at reflux temperature for 16 h to remove the phthalimido group and the *O*-acetyl groups. The obtained product was then fully acetylated with acetic anhydride in pyridine overnight to give **11** in 63% yield. Removal of protecting groups (*O*-acetyl groups and *O*-benzyl groups) was then performed by treatment of **11** with 0.1% NaOMe/MeOH for 2 h, following catalytic hydrogenation (Pd/C) to give the pentasaccharide **12** in 79% yield. Enzymatic sialylation at the 3^e-*O*-position of the terminal galactopyranosyl residue of **12** was achieved using recombinant α -(2 \rightarrow 3)-sialyltransferase^{16,17} and CMP-NeuAc, which afforded branched hexasaccharide **13** in 59% yield.

The ¹H NMR spectra of both compounds **12** and **13** are shown in Figure 2. Five anomeric proton (H-1) signals were observed in the ¹H NMR spectrum of **12** at 4.395 (H-1^a, Glc), 4.453 (H-1^b, Gal), 4.477 (H-1^c, Gal), 4.722 (H-1^d, GlcNAc), and 4.877 (H-1^e, Glc) ppm (the extra singlet under H-1^a is the resonance of H-4^b), whereas the equivalent





Figure 2. 500 MHz ^1H NMR spectra of compound 12 (A) and compound 13 (B) recorded in D_2O at 310 K.

anomeric signals of **13** were at 4.396 (H-1^a, Glc), 4.455 (H-1^b, Gal), 4.551 (H-1^c, Gal), 4.713 (H-1^d, GlcNAc), and 4.886 (H-1^e, Glc) ppm. Thus, sialylation at the 3-*O*-position resulted in a large increase in chemical shift (0.074 ppm) of the signal of H-1^e. More detailed conformational studies of **12** and **13** will be reported elsewhere.



EXPERIMENTAL

General methods. Optical rotations were measured at room temperature with a Perkin-Elmer 243 polarimeter, using a 10-cm 1-mL cell. ¹H and ¹³C NMR spectra were

recorded at 500 MHz and 125 MHz, respectively, with a Bruker AMX 500 instrument at 300 K unless otherwise noted. Chemical shifts are given in ppm relative to the signal of internal Me₄Si or indirectly to solvent signals 7.25 (CDCl₃), 2.225 (acetone in D₂O) for ¹H NMR spectra, and to the solvent signals 76.9 (CDCl₃), 31.55 (internal acetone) for ¹³C NMR spectra. The ¹H NMR resonances of oligosaccharides were assigned on the basis of 2D ¹H-homonuclear chemical-shift correlated (¹H-COSY) experiments. FAB and ES (electron spray) mass spectroscopic analyses were performed with a JEOL JMS-AX505H and a VG QUATTRO mass spectrometer, respectively.

Column chromatography was performed on Silica gel 60 (Merck, 230-400 mesh) and fractions were monitored by TLC on Silica gel 60 F₂₅₄ (Merck) unless otherwise noted. Detection was effected by examination under UV light and by charring with 5% sulphuric acid solution in ethanol. Solutions were concentrated at or below 40 °C and dried with anhydrous Na₂SO₄.

Methyl 4-*O*-(3-*O*-Allyl-2-*O*-benzyl-4,6-di-*O*-benzylidene-β-D-galactopyranosyl)-2,3,6-tri-*O*-benzyl-β-D-glucopyranoside (2). To a solution of compound **1** (0.8 g, 1.65 mmol) in DMF (15 mL) was added NaH (50%, 0.4 g, 8.33 mmol). The mixture was stirred at rt for 0.5 h. Benzyl bromide (1 mL, 8.42 mmol) was added to the mixture and the stirring was continued for another 3 h. Methanol (0.5 mL) was added to the mixture to destroy excess NaH, and then cold water (50 mL) was added. The solution was extracted with EtOAc (2 x 40 mL). The organic solution was subsequently washed with water, aq NaHCO₃, and water, then dried and concentrated to a residue. Purification by chromatography (EtOAc/hexane 1:2) gave **2** (1.1g, 78%) as a solid: [α]_D +1.6° (c 1.49, MeOH); ¹H NMR (CDCl₃) δ 3.006 (s, 1H, H-5^b), 3.317 (dd, 1H, H-3^b, J_{2,3} = 9.5 Hz, J_{3,4} = 3.4 Hz), 3.368 (dd, 1H, H-5^a), 3.418 (dd, 1H, H-2^a, J_{2,3} = 8.5 Hz), 3.552 (s, 3H, OMe), 3.622 (dd, 1H, H-3^a, J_{3,4} = 9.0 Hz), 3.710 (dd, 1H, H-2^b, J_{2,3} = 9.5 Hz), 3.726 (m, 1H, H-6^b), 3.860-3.883 (m, 2H, H-6^a, 6^b), 3.976 (dd, 1H, H-4^a, J_{4,5} = 9.3 Hz), 4.104 (d, 1H, H-4^b, J_{3,4} = 3.4 Hz), 4.170-4.226 (m, 3H, OCH₂CH=CH₂, H-6^a), 4.303 (d, 1H, H-1^a, J_{1,2} = 8.3 Hz), 4.348 and 4.539 (2d, 2H, CH₂Ph, J = 12.5 Hz), 4.476 (s, 1H, H-1^b, J_{1,2} = 8.4 Hz), 4.670-4.882 (m, 5H, 2.5 x CH₂Ph), 5.163 (d, 2H, one of CH₂Ph and one of CH₂CH=CH₂, J = 10.8 Hz), 5.283 (d, 1H, one of OCH₂CH=CH₂, J = 16.6 Hz), 5.492 (s, 1H, PhCH), 5.927 (m, 1H, OCH₂CH=CH₂), 7.159-7.498 (m, 25H, 5 x Ph).

Methyl 4-*O*-(3-*O*-Allyl-2,6-di-*O*-benzyl- β -D-galactopyranosyl)-2,3,6-tri-*O*-benzyl- β -D-glucopyranoside (3). To a mixture of sodium cyanoborohydride (1.0 g, 16 mmol), powdered molecular sieves 3Å (3.0 g), and compound **2** (1.0 g, 1.18 mmol) in THF (15 mL) a saturated solution of HCl in ethyl ether was added dropwise at 0 °C until the mixture became acidic (pH 3 with pH paper). Then the mixture was stirred further at 0 °C until the reaction was complete (2 h). The mixture was diluted with EtOAc (50 mL) and filtered through Celite. The filtrate was subsequently washed with water, aq NaHCO₃, and water, then dried and concentrated to a residue. Purification by chromatography (EtOAc/hexane 1:3) gave syrupy **3** (0.7 g, 69%): $[\alpha]_D^{+27.1^\circ}$ (*c* 0.8, MeOH); ¹H NMR (CDCl₃) δ 2.340 (s, 1H, OH-4^b), 3.271 (dd, 1H, H-3^b, $J_{2,3} = 9.3$ Hz, $J_{3,4} = 3.4$ Hz), 3.537 (s, 3H, OMe), 4.266 (d, 1H, H-1^a, $J_{1,2} = 7.8$ Hz), 4.364-4.548 (m, 5H, 2 x CH₂Ph and H-1^b), 4.678-4.967 (m, 6H, 3 x CH₂Ph), 5.161 (d, 1H, one of CH₂CH=CH₂, $J = 10.0$ Hz), 5.263 (d, 1H, one of OCH₂CH=CH₂, $J = 17.2$ Hz), 5.910 (m, 1H, OCH₂CH=CH₂), 7.198-7.364 (m, 25H, 5 x Ph); HRFABMS Calcd for C₅₁H₅₈O₁₁Li (M+Li): 853.4139. Found: 853.4131.

Methyl O-(2,3,4,6-Tetra-*O*-acetyl- β -D-glucopyranosyl)-(1 \rightarrow 4)-O-(3-*O*-allyl-2,6-di-*O*-benzyl- β -D-galactopyranosyl)-(1 \rightarrow 4)-2,3,6-tri-*O*-benzyl- β -D-glucopyranoside (5). A mixture of **3** (0.6 g, 0.7 mmol), **4** (0.7 g, 1.4 mmol), and powdered molecular sieves 4Å (1.0 g) in dichloromethane (15 mL) was stirred at rt for 1 h. The mixture was cooled to -45 °C and trimethylsilyl triflate (150 μ L) was added. The mixture was stirred at -45 °C for 1 h, and was then neutralized with a solution of 2,6-lutidine (0.5 mL) in dichloromethane (20 mL). The filtrate was subsequently washed with water, 1M HCl, and water, then dried and concentrated to a residue. Purification by chromatography (EtOAc/hexane 2:3) gave **5** (0.73 g, 75%) as a solid: $[\alpha]_D^{+25.9^\circ}$ (*c* 1.1, MeOH); ¹H NMR (CDCl₃) δ 1.973, 1.990, 2.008, 2.049 (4s, 3H each, 4 x OAc), 3.230 (dd, 1H, H-3^b, $J_{2,3} = 9.5$ Hz, $J_{3,4} = 3.4$ Hz), 3.528 (s, 3H, OMe), 4.851 (d, 1H, H-1^c, $J_{1,2} = 8.1$ Hz), 4.981 (dd, 1H, H-2^c, $J_{2,3} = 9.5$ Hz), 5.100 (t, 1H, H-4^c, $J_{3,4} = J_{4,5} = 9.5$ Hz), 5.161-5.243 (m, 2H, H-3^c and one of OCH₂CH=CH₂), 5.316 (d, 1H, one of OCH₂CH=CH₂, $J = 17$ Hz), 5.910 (m, 1H, OCH₂CH=CH₂), 7.195-7.466 (m, 25H, 5 x Ph); HRFABMS Calcd for C₆₅H₇₆O₂₀Li (M+Li): 1183.5090. Found: 1183.5098.

Methyl *O*-(2,3,4,6-Tetra-*O*-acetyl- β -D-glucopyranosyl)-(1 \rightarrow 4)-*O*-(2,6-di-*O*-benzyl- β -D-galactopyranosyl)-(1 \rightarrow 4)-2,3,6-tri-*O*-benzyl- β -D-glucopyranoside (6). A mixture of **5** (0.45 g, 0.38 mmol) and PdCl₂ (0.6 g) in methanol (10 mL) was stirred at rt until the starting material was consumed (2 h). The mixture was filtered through Celite and the solid residue was extracted with EtOAc (50 mL). The combined organic solution was subsequently washed with water, aq NaHCO₃, and water, then dried and concentrated to a residue. Purification by chromatography (EtOAc/hexane 1:1) gave **6** (0.31 g, 71%) as a solid: [α]_D +14.5° (c 1.6, MeOH); ¹H NMR (CDCl₃) δ 1.944, 1.965, 2.000, 2.017 (4s, 3H each, 4 x OAc), 2.298 (d, 1H, OH-3^b, J = 4.4 Hz), 3.529 (s, 3H, OMe), 4.261 (d, 1H, H-1^a, J_{1,2} = 7.7 Hz), 4.394 (d, 1H, H-1^b, J_{1,2} = 8.3 Hz), 4.861 (d, 1H, H-1^c, J_{1,2} = 8.4 Hz), 4.986 (dd, 1H, H-2^c, J_{2,3} = 9.5 Hz), 5.092 (t, 1H, H-4^c, J_{3,4} = J_{4,5} = 9.5 Hz), 5.195 (t, 1H, H-3^c, J_{2,3} = J_{3,4} = 9.5 Hz), 7.198-7.444 (m, 25H, 5 x Ph); HRFABMS Calcd for C₆₂H₇₂O₂₀Li (M+Li): 1143.4777. Found: 1143.4783.

2-(Trimethylsilyl)ethyl 4-*O*-(2,3,4,6-Tetra-*O*-acetyl- β -D-galactopyranosyl)-3,6-di-*O*-acetyl-2-deoxy-2-phthalimido- β -D-glucopyranoside (8). A mixture of compound **7** (0.2 g, 0.26 mmol) in acetic anhydride/pyridine (1:1, 2 mL) was stirred overnight. The solvent was removed by co-distillation with toluene. The residue was purified by chromatography (EtOAc/hexane 1:1) to give crystalline **8** (0.17 g, 81%): mp 133-134 °C (EtOAc/Hexane); [α]_D +12.9° (c 0.49, CH₂Cl₂); ¹H NMR (CDCl₃) δ 0.159 (s, 9H, SiMe₃), 0.714, 0.788 (2m, 1H each, CH₂CH₂SiMe₃), 1.877, 1.941, 2.017, 2.044, 2.112 (2) (5s, 6 x OAc), 4.522 (d, 1H, H-1^b, J_{1,2} = 7.4 Hz), 5.308 (bs, 1H, H-4^b), 5.355 (d, 1H, H-1^a, J_{1,2} = 8.4 Hz), 5.708 (t, 1H, H-3^a, J_{2,3} = J_{3,4} = 9.0 Hz), 7.702, 7.821 (2bs, 2H each, Phth); HRFABMS Calcd for C₃₇H₄₉NO₁₈SiLi (M+Li): 830.2879. Found: 830.2875.

Anal. Calcd for C₃₇H₄₉O₁₈Si: C 53.9; H 6.0; N 1.7. Found: C 53.7; H 6.1; N 1.8.

4-*O*-(2,3,4,6-Tetra-*O*-acetyl- β -D-galactopyranosyl)-3,6-di-*O*-acetyl-2-deoxy-2-phthalimido- β -D-glucopyranosyl trichloroacetimidate (9). **Method 1:** To a stirred solution of **8** (0.16 g, 0.19 mmol) in dichloromethane (5 mL) was added boron trifluoride etherate (0.4 mL). The stirring was continued at 0 °C for 2 h, and the solution was then diluted with dichloromethane (20 mL), washed subsequently with water, aq NaHCO₃, and water, then dried and concentrated to a residue. To a solution of the above residue and

trichloroacetonitrile (0.4 mL) in dichloromethane (5 mL) at 0 °C was added DBU (50 μ L). The mixture was stirred for 2 h at 0 °C, and then concentrated. Purification by chromatography (EtOAc/hexane 1:1) gave **9** (66 mg, 40%) as a solid: $[\alpha]_D +39.6^\circ$ (*c* 2.5, CH₂Cl₂); lit. $[\alpha]_D +40.9^\circ$,⁹ $[\alpha]_D +43^\circ$;¹¹ ¹H NMR (CDCl₃) δ 1.904, 1.937, 2.032, 2.039, 2.112, 2.123 (6s, 3H each, 6 x OAc), 4.532 (d, 1H, H-1^b, $J_{1,2} = 7.9$ Hz), 5.314 (d, 1H, H-4^b, $J_{3,4} = 2.9$ Hz), 5.858 (dd, 1H, H-3^a, $J_{2,3} = 8.0$ Hz, $J_{3,4} = 10.0$ Hz), 6.594 (d, 1H, H-1^a, $J_{1,2} = 8.8$ Hz), 7.691, 7.810 (2m, 2H each, Phth), 8.618 (s, 1H, NH).

Method 2: To a solution of **8** (0.10 g, 0.12 mmol) in dichloromethane (4 mL) was added trifluoroacetic acid (2 mL). The mixture was stirred for 2 h at rt. EtOAc (20 mL) was added and the solution was subsequently washed with water, aq NaHCO₃, and water, then dried and concentrated to a residue. To a solution of the above residue and trichloroacetonitrile (0.5 mL) in dichloromethane (8 mL) was added anhydrous K₂CO₃ (0.1 g). The mixture was stirred for 4 h and the filtrate was concentrated. Purification by chromatography (EtOAc/hexane 1:1) gave **9** (80 mg, 77%).

Methyl O-(2,3,4,6-Tetra-O-acetyl- β -D-galactopyranosyl)-(1 \rightarrow 4)-O-(3,6-di-O-acetyl-2-deoxy-2-phthalimido- β -D-glucopyranosyl)-(1 \rightarrow 3)-O-[2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyl-(1 \rightarrow 4)-O]-(2,6-di-O-benzyl- β -D-galactopyranosyl)-(1 \rightarrow 4)-2,3,6-tri-O-benzyl- β -D-glucopyranoside (10**).** A mixture of **6** (60 mg, 0.053 mmol), **9** (60 mg, 0.069 mmol), and powdered molecular sieves 4 \AA (0.1 g) in dichloromethane (3 mL) was stirred at rt for 1 h. The mixture was cooled to -45 °C and trimethylsilyl triflate (20 μ L) was added. The mixture was stirred at that temperature for 1.5 h, and was then neutralized with a solution of 2,6-lutidine (0.5 mL) in dichloromethane (20 mL). The filtrate was subsequently washed with water, 1M HCl, and water, then dried and concentrated to a residue. Purification by chromatography (EtOAc/hexane 1:1) gave **10** (40 mg, 41 %) as a solid: $[\alpha]_D +18^\circ$ (*c* 2.3, CH₂Cl₂); ¹H NMR (CDCl₃) δ 1.853, 1.857, 1.954, 1.986, 1.987, 2.005, 2.038, 2.066, 2.078, 2.117 (10s, 3H each, 10 x OAc), 3.428 (s, 3H, OMe), 4.558 (d, 1H, H-1^e, $J_{1,2} = 8.0$ Hz), 4.611 (d, 1H, H-1^c, $J_{1,2} = 9.9$ Hz), 5.125 (bt, 2H, H-2^e, 4^c), 5.340 (m, 2H, H-3^c, 4^e), 5.589 (d, 1H, H-1^d, $J_{1,2} = 8.4$ Hz), 5.735 (dd, 1H, H-3^d, $J_{2,3} = 10.2$ Hz, $J_{3,4} = 8.5$ Hz), 6.821-7.506 (m, 29H, Phth and 5 x Ph); ¹³C NMR (CDCl₃) δ 99.99, 101.17, 101.31, 101.61, 104.64 (5 x C-1); FABMS Calcd for C₉₄H₁₀₇NO₃₇Li (M+Li):1848.67. Found: 1848.80.

Methyl *O*-(2,3,4,6-Tetra-*O*-acetyl- β -D-galactopyranosyl)-(1 \rightarrow 4)-*O*-(3,6-di-*O*-acetyl-2-acetamido-2-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 3)-*O*-[2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyl-(1 \rightarrow 4)-*O*]-[2,6-di-*O*-benzyl- β -D-galactopyranosyl)-(1 \rightarrow 4)-2,3,6-tri-*O*-benzyl- β -D-glucopyranoside (11). A mixture of **10** (38 mg, 0.021 mmol) and hydrazine hydrate (0.5 mL) in 95% EtOH (3 mL) was refluxed for 16 h. Upon cooling, the solvent was evaporated and the residue was treated with acetic anhydride/pyridine (1:1, 2 mL) overnight. The solvent was removed by co-distillation with toluene, and the residue was purified by chromatography (EtOAc/hexane 3:1) to give **11** (23 mg, 62%) as a solid: $[\alpha]_D +13.7^\circ$ (*c* 2.2, MeOH); $^1\text{H NMR}$ (CDCl_3) δ 1.702 (NAc), 1.953, 1.956, 1.967, 2.000, 2.011, 2.028, 2.037 (2), 2.045, 2.127 (9s, 10 x OAc), 3.486 (s, 3H, OMe), 4.406 (d, 1H, H-1^b, $J_{1,2} = 7.4$ Hz), 4.476 (d, 1H, H-1^c, $J_{1,2} = 8.3$ Hz), 5.080 (d, 1H, H-1^d, $J_{1,2} = 9.0$ Hz), 5.122 (t, 1H, H-4^c, $J_{3,4} = J_{4,5} = 9.8$ Hz), 5.336 (m, 2H, H-3^c, 4^e), 7.186-7.457 (m, 25H, 5 x Ph); $^{13}\text{C NMR}$ (CDCl_3) δ 20.74-24.98 (11 x CH_3CO), 100.19, 101.32, 102.31, 102.52, 104.67 (5 x C-1), 169.28-170.75 (11 x CH_3CO); FABMS Calcd for $\text{C}_{88}\text{H}_{107}\text{NO}_3\text{Li}$ (M+Li): 1760.67. Found: 1760.76.

Methyl *O*-(β -D-Galactopyranosyl)-(1 \rightarrow 4)-*O*-(2-acetamido-2-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 3)-*O*-[β -D-glucopyranosyl-(1 \rightarrow 4)-*O*]-(β -D-galactopyranosyl)-(1 \rightarrow 4)- β -D-glucopyranoside (12). A solution of **11** (20 mg, 11.4 μmol) in 0.1% NaOMe/MeOH (3 mL) was stirred at rt for 2 h. The solution was neutralized with ion-exchange resin Dowex 50 (H^+), and the filtrate was concentrated to a residue. A mixture of above residue and 10% Pd/C (50% water, 30 mg) in H_2O -MeOH-AcOH (1:1:1, 3 mL) was subjected to a hydrogenation (40 psi) for 3 h. The filtrate was concentrated and purified by passage through a Sephadex G-10 column. The fractions containing the major component were lyophilized to give **12** (8.0 mg, 79%) as an amorphous solid: $[\alpha]_D -7.5^\circ$ (*c* 0.8, H_2O); $^1\text{H NMR}$ (D_2O , 310 K) δ 2.029 (s, 3H, NAc), 3.277 (dd, 1H, H-2^c, $J_{2,3} = 8.7$ Hz), 3.303 (dd, 1H, H-2^a, $J_{2,3} = 8.3$ Hz), 3.568 (s, 3H, OMe), 3.939 (d, 1H, H-4^e, $J_{3,4} = 3.1$ Hz), 4.387 (bs, 1H, H-4^b), 4.395 (d, 1H, H-1^a, $J_{1,2} = 8.2$ Hz), 4.453 (d, 1H, H-1^b, $J_{1,2} = 8.1$ Hz), 4.477 (d, 1H, H-1^c, $J_{1,2} = 7.9$ Hz), 4.722 (d, 1H, H-1^d, $J_{1,2} = 8.2$ Hz), 4.877 (d, 1H, H-1^e, $J_{1,2} = 8.0$ Hz); $^{13}\text{C NMR}$ (D_2O) δ 23.51 (CH_3CON), 56.56 (C-2^d), 58.47 (OMe), 61.28, 61.45, 62.08 (2), 69.82, 71.02, 71.59, 72.24, 73.48, 73.79, 74.02, 74.94, 75.64 (2), 75.93, 76.05, 76.32, 76.63, 76.93, 77.18, 79.56, 79.70, 81.17, 103.36, 104.17,

104.28, 104.33, 104.40 (5 x C-1), 176.09 (CH₃CON); FABMS Calcd for C₃₃H₅₇NO₂₆Na (M+Na): 906.80. Found: 906.80.

Methyl *O*-(5-Acetamido-3,5-dideoxy-D-glycero- α -D-galacto-2-nonulopyranosylonic acid)-(2 \rightarrow 3)-*O*-(β -D-galactopyranosyl)-(1 \rightarrow 4)-*O*-(2-acetamido-2-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 3)-*O*-[β -D-glucopyranosyl-(1 \rightarrow 4)-*O*]-(β -D-galactopyranosyl)-(1 \rightarrow 4)- β -D-glucopyranoside (13). A solution of **12** (4.0 mg, 4.5 μ L), CMP-NeuAc (3 mg) in water (0.5 mL) was adjusted to pH 7.5 by 1M sodium cacodylate. To the above solution were added 1% HSA (10 μ L), alkaline phosphatase (5 U) and α -(2 \rightarrow 3)-sialyltransferase (30 mU) and the pH was adjusted again to 7.5 using 1 M sodium cacodylate solution, and the mixture was kept at rt for 24 h. Additional CMP-NeuAc (3 mg) was added and the mixture was incubated for another 24 h, when TLC (*n*-BuOH/AcOH/H₂O 2:1:1) indicated the reaction was almost complete. The mixture was purified on a column of Bio-gel P-2 (0.02 M acetic acid/pyridine buffer, pH 5.5). The fractions containing major product were lyophilized to give **13** (3.2 mg, 59%) as an amorphous solid: [α]_D -4.0° (*c* 0.3, H₂O); ¹H NMR (D₂O, 310 K) δ 1.794 (t, 1H, H-3a^f, J_{3a,4} = J_{3a,3e} = 12.1 Hz), 2.027 and 2.032 (2s, 3H each, 2 x NAc), 2.767 (dd, 1H, H-3e^f, J_{3e,4} = 4.5 Hz, J_{3a,3e} = 12.1 Hz), 3.267 (dd, 1H, H-2^c, J_{2,3} = 9.3 Hz), 3.283 (dd, 1H, H-2^a, J_{2,3} = 8.3 Hz), 3.569 (s, 3H, OMe), 4.103 (dd, 1H, H-3^e, J_{3,4} = 2.8 Hz, J_{2,3} = 9.8 Hz), 4.388 (bs, 1H, H-4^b), 4.396 (d, 1H, H-1^a, J_{1,2} = 7.9 Hz), 4.455 (d, 1H, H-1^b, J_{1,2} = 7.8 Hz), 4.551 (d, 1H, H-1^c, J_{1,2} = 7.8 Hz), 4.713 (d, 1H, H-1^d, J_{1,2} = 8.2 Hz), 4.886 (d, 1H, H-1^c, J_{1,2} = 8.0 Hz); ¹³C NMR (D₂O) δ 22.87, 23.08 (2 x CH₃CON), 40.50 (C-3^f), 52.54 (C-5^f), 56.13 (C-2^d), 58.04 (OMe), 60.87, 61.04, 61.64, 61.86, 63.48, 68.34, 68.97, 69.17, 70.22, 70.62, 71.16, 72.62, 73.01, 73.59, 73.75, 74.53, 75.23, 75.52, 75.63, 75.88, 76.04, 76.37, 76.50, 76.77, 79.17, 82.78, 100.67 (C-2^f), 102.91, 103.46, 103.85, 103.91, 104.03 (5 x C-1), 175.66, 175.89 (2 x CH₃CON); ESMS Calcd for C₄₄H₇₃N₂O₃₄Na: 1197.1 [M]. Found: 1197.3 [M]⁺ (positive mode); 1174.0 [M-Na]⁻ (negative mode).

ACKNOWLEDGEMENT

This is NRCC publication No. 39520 and the work was supported in part by National Institutes of Health (NIH) grant AI-23339. We thank Dr. J. C. Paulson of Cytel

Corporation for the generous gift of recombinant α -(2 \rightarrow 3)-sialyltransferase. We are also grateful to Mr. F. Cooper and Mr. D. Krajcarski for the mass spectroscopic analysis, and Ms. A. Webb for the elemental analysis.

REFERENCES

1. C. J. Baker and M. S. Edwards, in J. S. Remington and J. O. Klein (ed.), *Infectious Diseases of the Fetus and Newborn Infant*. The W. B. Saunders Co., Philadelphia, 1990, p742.
2. H. J. Jennings, E. Katzenellenbogen, C. Lugowski, and D. L. Kasper, *Biochemistry*, **22**, 1258 (1983).
3. R. C. Lancefield, *J. Exp. Med.*, **67**, 25 (1938).
4. M. R. Wessels, L. C. Paoletti, A. K. Rodewald, F. Michon, J. DiFabio, H. J. Jennings, and D. L. Kasper, *Infection and Immunity*, **61**, 4760 (1993).
5. H. J. Jennings, E. Katzenellenbogen, C. Lugowski, F. Michon, R. Roy, and D. L. Kasper, *Pure Appl. Chem.*, **56**, 893 (1984), and references cited therein.
6. A. Maranduba and A. Veyrieres, *Carbohydr. Res.*, **151**, 105 (1986).
7. P. J. Garegg, H. Hultberg, and S. Wallin, *Carbohydr. Res.*, **108**, 97 (1982).
8. G. Ekborg, T. Curenton, N. Rama Krishna, and L. Roden, *J. Carbohydr. Chem.*, **9**, 15 (1990).
9. K. K. Sadozai, T. Nukada, Y. Ito, Y. Nakahara, T. Ogawa, and A. Kobata, *Carbohydr. Res.*, **157**, 101 (1986).
10. G. Grundler and R. R. Schmidt, *Carbohydr. Res.*, **135**, 203 (1985).
11. H. Ammann and G. Dupius, *Can J. Chem.*, **66**, 1651 (1988).
12. W. Zou, Jean-Robert Brisson, Qing-Ling Yang, Mark van der Zwan, and H. J. Jennings, *To be published*.
13. T. Murase, H. Ishida, M. Kiso, and A. Hasegawa, *Carbohydr. Res.*, **184**, C1 (1988); **188**, 71(1989); K. Jansson, S. Ahlfors, T. Frejd, J. Kihlberg, G. Magnusson, J. Dahmen, G. Noori, and K. Stenvall, *J. Org. Chem.*, **53**, 5629 (1988).
14. S. Sato, Y. Ito, T. Nukada, Y. Nakahara, and T. Ogawa, *Carbohydr. Res.*, **167**, 197 (1987).
15. B. Wegman and R. R. Schmidt, *J. Carbohydr. Chem.*, **6**, 357 (1987); R. R. Schmidt, J. Michel, and M. Roos, *Liebigs Ann. Chem.*, 1343 (1984); R. R. Schmidt and M. Stumpp, *Liebigs Ann. Chem.*, 1249 (1983).
16. C. Unverzagt, H. Kunz, J. C. Paulson, *J. Am. Chem. Soc.*, **112**, 9308 (1990).
17. R. L. Halcomb, H. Huang, and C.-H. Wong, *J. Am. Chem. Soc.*, **116**, 11315 (1994).